Kinfo
Anteris Technologies Ltd. logo

Anteris Technologies Ltd.

AVRNASDAQHealthcare·US · USD
$9.77
+0.28 (+2.95%)
Prices as of July 10, 2026 · market closed

Price

Key statistics

Valuation
Market cap951.03M USD
Enterprise value672.04M USD
Trailing P/E-3.83
Forward P/E-9.97
PEG ratio0.07
Price / sales513.79
Price / book3.41
Profitability
Gross margin0.00%
Operating margin-4859.72%
Profit margin0.00%
Return on assets-33.99%
Return on equity-59.21%
Income (TTM)
Revenue1.85M USD
Gross profit1.38M USD
EBITDA-94.43M USD
Net income-95.30M USD
Diluted EPS-$2.22
Rev. growth (YoY)-11.20%
Balance sheet
Total cash282.70M USD
Total debt3.73M USD
Debt / equity1.34
Current ratio20.93
Book value / share$2.86
Cash flow (TTM)
Operating cash flow-84.99M USD
Levered free cash flow-52.66M USD
Shares & price
Shares outstanding97.34M
Float60.31M
Held by institutions66.85%
Beta0.73
50-day MA$8.66
200-day MA$6.06
52-week high$11.06
52-week low$2.85
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-02-26-0.56-0.75−33.93%2026-02-033.323.33+0.30%2025-11-12-0.57-0.62−8.77%2025-08-11-0.48-0.58−20.83%
About Anteris Technologies Ltd.

Anteris Technologies Ltd. is a structural heart company that designs, develops, and commercializes innovative medical devices for treating heart valve diseases. Its flagship product, the DurAVR Transcatheter Heart Valve system, features a single-piece, native-shaped biomimetic design engineered to mimic the performance of a healthy aortic valve, addressing aortic stenosis through minimally invasive procedures. The system incorporates ADAPT anti-calcification tissue, which transforms xenograft material into durable bioscaffolds resembling human tissue, and the ComASUR delivery system, a balloon-expandable mechanism with a reinforced steerable catheter for precise navigation through heart anatomy. Anteris Technologies Ltd. operates across key markets including the United States, Germany, Australia, Switzerland, and Sweden, with a focus on advancing cardiac care via science-driven innovations. Headquartered in Toowong, Australia, the company partners with interventional cardiologists and cardiac surgeons to deliver paradigm-shifting hemodynamic performance and deliverability in transcatheter aortic valve replacement therapies.

Sector
Healthcare
Industry
Medical Instruments & Supplies
CEO
Mr. Wayne Geoffrey Paterson
Employees
174
Headquarters
Toowong, QLD, Australia

Frequently asked questions about Anteris Technologies Ltd.